| http://www.w3.org/ns/prov#value | - Looking ahead, we plan to initiate a Phase IB clinical study with CUDC-101 with the intent of enrolling additional patients at the established MTD of 275 milligrams per meter squared in tumor types including gastric, head and neck, breast and liver cancers to assess different dosing regimens and to seek additional signals of activity and to help guide future clinical studies.
|
